Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles

Table 1 Embedding ratio and drug loading of VACV-PBCA-NP

Batch NO.	Embedding ratio (%)	Drug loading (%)
961010	85.10	12.15
961012	83.75	10.51
961015	85.70	10.93
Average	84.85	11.20

Table 2 Stability results of VACV-PBCA-NP

Temperature (°C)	0 month				3 months
	D/nm	C	pH	Color	D/nm	C	pH	Color
3-5	107.28	0.49	5.34	white	110.42	0.47	5.25	white
15-25	107.28	0.49	5.34	white	109.37	0.48	5.05	white
37 (RH75%)	107.28	0.49	5.34	white	105.61	0.43	4.10	white

C: Mg/ampoule; D: Diameter.

Table 3 Relative content in various organs 15 min after iv administration of VACV-PBCA-NP and VACV respectively (%, n = 3)

Sample	Heart	Liver	Spleen	Lung	Kidney	Blood
VACV-PBCA-NP	0.99	74.49	2.46	2.89	9.36	9.82
VACV	2.14	24.92	2.44	3.01	51.15	16.54

Table 4 The results of single factor variance analysis of the main pharmacokinetic parameters of VACV-PBCA-NP and VACV

Factors	A	B	DF	F (test)	F (criterion)	P
AUC	223.34	6.40	1.8	35.87	11.30	< 0.01
MRT (h)	244.58	0.95	1.8	28.83	11.30	< 0.01

A: VACV-PBCA-NP; B: VACV; DF: Degree of freedom.